Table 1

Study population

CharacteristicsControl subjects
N=87
UC
N=127
p Value*
Male/female (%)39/48 (45/55)74/53 (58/42)0.07†
Median (IQR) age (years)41.5 (30–53)43 (32–55)0.45‡
Median (IQR) duration of disease (years)NA9 (4–15)NA
Median (IQR) BMI24.3 (22–27)25 (22–28)0.37‡
MedicationNANA
5-Aminosalicylic acid (%)92 (72)
Azathioprine/6-mercaptopurine (%)18 (14)
Corticosteroids (%)18 (14)
Anti-TNF (%)54 (43)
Disease activityNANA
Quiescent disease (Mayo 0–1)88 (69)
Moderate disease (Mayo 2)21 (17)
Severe disease (Mayo 3)18 (14)
Mayo endoscopy subscoreNANA
Mayo 018 (14)
Mayo 114 (11)
Mayo 215 (12)
Mayo 314 (11)
Disease extent
E1 proctitis (%)NA25 (20)NA
E2 left-sided colitis (%)53 (42)
E3 pancolitis (%)49 (39)
Smoking (%)15 (17)16 (13)0.43‡
Appendectomy (%)6 (7)6 (5)0.55‡
  • Groups were compared by non-parametric.

  • *p Value <0.05 was considered significant.

  • †χ2 test.

  • ‡Mann–Whitney U test.

  • BMI, body mass index; Control subjects, both healthy subjects and unaffected partners of UC patients; NA, not applicable; TNF, tumour necrosis factor; UC, ulcerative colitis.